A phase IB multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab (AMG 827), a human anti-interleukin 17 receptor (IL-17R) antibody, in rheumatoid arthritis

Authors
Category Primary study
ConferenceArthritis and Rheumatism
Year 2012
This article has no abstract
Epistemonikos ID: 5c137fcc6891f03aef6da48eb98cc1614ffd3c8f
First added on: Apr 30, 2026